GLP-1 (7–37)
PreclinicalEndogenous incretin peptide
Research material. Not for human or animal consumption.
Research overview
GLP-1 (7-37) is one of the two active forms of native glucagon-like peptide-1, produced by intestinal L cells after meals (the other is the amidated GLP-1 7-36). It stimulates insulin release only when glucose is raised, suppresses glucagon and slows gastric emptying. Its half-life in blood is only about two minutes because dipeptidyl peptidase-4 (DPP-4) cuts off the first two amino acids, so it is used as a physiological reference and assay standard rather than a drug.
Laboratory, computational, ex vivo or animal model research is the main evidence base.
Questions about GLP-1 (7–37)
PRODUCT QUESTIONSWhat is GLP-1 (7–37)?
GLP-1 (7–37) is a 31 residue peptide derived from proglucagon, numbered from position 7 because the first six residues of the precursor are removed. It has a free acid C terminus, unlike the amidated 7 to 36 form.
What research has been published on GLP-1 (7–37)?
The native peptide is used to define glucagon like peptide 1 receptor activity in cell assays, in glucose clamp studies of insulin secretion and in work on breakdown by DPP 4 and neprilysin. It is the reference against which long acting drugs such as liraglutide and semaglutide were designed.
What batch documentation should accompany GLP-1 (7–37)?
GLP-1 (7–37): Ask for the COA and analytical reports for the batch being quoted. Ask for mass spectrometry, HPLC purity that resolves the DPP 4 product GLP 1 (9 to 37) and the amidated 7 to 36 form, plus peptide content for accurate dosing in assays.
How should GLP-1 (7–37) storage conditions be assessed?
Store GLP-1 (7–37) lyophilised at −20°C. It forms fibrils in solution, especially when agitated or near neutral pH, so prepare solutions fresh, avoid vortexing and use low binding tubes.